Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...

Autobahn Therapeutics raised $100 million in a Series C this week, pledging to use the new funding for its pipeline of drug candidates for depression and other central nervous system disorders.

"By leveraging USC's scientific expertise and Autobahn's drug discovery capabilities, we are accelerating the development of novel therapeutics that address critical medical needs and improve ...

Over the past several years, environmentalists have established the autobahn, Germany's high-speed national motorway, as one of the primary battlegrounds on which to wage a war on greenhouse ...